Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Erectile function at three months after COVID-19 recovery

researchers explored the manifestation of erectile dysfunction after COVID-19 recovery.

24 Oct 2022

COVID pandemic saw a huge drop in patients seeking treatment for clinical depression

In the first study of its kind, German researchers have shown that the COVID pandemic saw a huge drop in the number of patients being admitted to hospital for clinical depression.

17 Oct 2022

Deep brain stimulation as obsessive-compulsive disorder treatment

In a recent study published in the Journal of Neurology, Neurosurgery & Psychiatry, researchers investigated the effectiveness of deep brain stimulation (DBS) against treatment-resistant obsessive-compulsive disorder (OCD).

25 Sep 2022

Why fatigue from long COVID goes beyond simply feeling tired

In a recent study posted to the medRxiv* preprint server, researchers in the Netherlands examined the role of inflammatory genes, cytotoxic T-lymphocytes (CD8+ T cells), and pro-inflammatory cytokines in long-lasting severe fatigue experienced by a large number of coronavirus disease 2019 (COVID-19) patients.

21 Sep 2022

Native Hawaiians/Pacific Islanders deeply affected by the COVID-19 pandemic, studies report

Native Hawaiians/Pacific Islanders, or NH/PIs, comprising more than 20 ethnic groups hailing from Polynesia, Micronesia, and Melanesia, are understudied despite being the third fastest growing racial group in the United States. Two studies now report that NH/PIs have been deeply affected by the COVID-19 pandemic.

19 Sep 2022

Nutritional approaches targeting gut microbiome could improve brain disorders

A new review published in the Clinical Nutrition and Metabolic Care journal focused on studies that utilized the dietary gut microbiota–target interventions to improve mental health conditions. It also discussed some suggestions for developing more robust and informative interventions for diet–microbiome studies.

15 Sep 2022

HKUMed team estimates a moderate link between antipsychotic use and breast cancer by over 30%

A research team from the Centre for Safe Medication Practice and Research (CSMPR), Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong (HKUMed) conducted the world's first systematic review and meta-analysis of observational studies with over two million individuals and estimated a moderate association between antipsychotic use and breast cancer by over 30%.

9 Sep 2022

Magnus’ SAINT Neuromodulation System receives 510(k) clearance from FDA for treatment of major depressive disorder

Magnus Medical, Inc., a medical device company and developer of brain stimulation technology for treatment of neuropsychiatric disorders, today announced it received 510(k) clearance from the U.S. Food & Drug Administration for the SAINTTM Neuromodulation System for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications in the current episode.

6 Sep 2022

No one-size-fits-all AI program exists for all preventive treatments

A Rutgers analysis of dozens of artificial intelligence (AI) software programs used in precision, or personalized, medicine to prevent, diagnose and treat disease found that no program exists that can be used for all treatments.

18 Aug 2022

Study identifies an optimal rTMS treatment regimen for older adults

A new study published in Frontiers in Aging Neuroscience is the first to identify an optimal Repetitive Transcranial Magnetic Stimulation (rTMS) treatment regimen for older adults with treatment-resistant depression, according to researchers at Hinda and Arthur Marcus Institute for Aging Research and the Deanna and Sidney Wolk Center for Memory Health at Hebrew SeniorLife.

16 Aug 2022

Suicidal ideation may have increased significantly during COVID-19 lockdown

The lockdowns during the COVID-19 pandemic had a significant effect on levels of suicidal ideation, a new study finds.

8 Aug 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 21 Jul 2022

Study reveals the prevalence of suicide ideation, attempts among people with premenstrual dysphoric disorder

A new global study published in BMC Psychiatry reports that 34% of people with premenstrual dysphoric disorder have attempted suicide.

13 Jun 2022

Combining psychotherapy with antidepressants does not improve outcomes in severely depressed patients

Antidepressants are the first-choice treatment for severe depression. Antidepressant use is often supplemented by psychotherapy.

6 Jun 2022

Treating pediatric psychiatric disorders with psychotropic drugs reduces later substance use disorder risk

One half of psychiatric and substance use disorders start by the age of 18; three-quarters by age 24. While these are concerning statistics, a new study from Massachusetts General Hospital finds that treating psychiatric disorders with psychotropic medications in children and adolescents does not increase the risk of developing substance use, misuse, or substance use disorder (SUD).

19 May 2022

New mouse model shows the connection between stress, depression and cardiovascular disease risk

Results from a new mouse model may aid in understanding how depression and prolonged and severe stress increase the risk of cardiovascular disease, according to preliminary research presented at the American Heart Association's Vascular Discovery: From Genes to Medicine Scientific Sessions 2022.

13 May 2022

Healthy Mediterranean diet helps young men to beat depression

Depression is a common mental health condition that affects approximately 1 million Australians each year. It is a significant risk factor for suicide, the leading cause of death in young adults.

9 May 2022

Researchers show how chronic pain leads to maladaptive anxiety in mice

Hokkaido University researchers have shown how chronic pain leads to maladaptive anxiety in mice, with implications for treatment of chronic pain-related psychiatric disorders in humans.

27 Apr 2022

The effect of antidepressants on patient-reported health-related quality of life

A new study published in PLoS ONE aimed to investigate the effect of using antidepressant medications on the HRQoL of patients with depression.